论文部分内容阅读
急性心肌梗死(AMI)的早期再灌注治疗明显减低死亡率,但AMI后左室重构引起的心衰仍然是一大难题。实验研究发现,血源性及骨髓源性干细胞移植对改善AMI后的重构有利。缺血性心脏病患者的自体干细胞移植的安全性及可行性尚不明确。 方法 20例AMI患者,年龄为18～75岁,发病(4.3±1.5)天后接受梗死相关动脉内灌注骨髓源性干细胞(BMCs)者9例,接受血源性干细胞(CPCs)者11例。BMCs在移植当天早上采
Early reperfusion of acute myocardial infarction (AMI) significantly reduces mortality, but heart failure due to left ventricular remodeling after AMI remains a major challenge. Experimental study found that blood-derived and bone marrow-derived stem cell transplantation to improve the reconstruction after AMI beneficial. The safety and feasibility of autologous stem cell transplantation in patients with ischemic heart disease is not yet clear. Methods Twenty patients with AMI were aged 18 to 75 years. Nine patients received infarction-related intra-arterial infusion of bone marrow-derived stem cells (BMCs) and 11 received blood-derived stem cells (CPCs) after the onset of (4.3 ± 1.5) days. BMCs were collected on the morning of transplantation